UK's Vaccitech Raises $27 Million, Co-Led by Sequoia China

Vaccitech, an Oxford University spinout that is developing a universal flu vaccine along with other vaccine products, closed a $27 million Series A financing. The round was co-led by GV (formerly Google Ventures), Sequoia China , and existing backer Oxford Sciences Innovation. A clinical stage company, Vaccitech is developing six products that induce cellular immune responses using non-replicating viral vectors, either for treatment or prophylaxis, including a vaccine for prostate cancer treatment. More details.... Share this with colleagues: // //